In a preclinical study for CLL, pirtobrutinib was proven to continuously inhibit the BCR pathway in both wild-type and C481S-mutant BTK CLL cells [52], providing a rationale for the treatment of patients refractory to cBTKis. Here, BCR is linked to B-cell chronic lymphocytic leukemia.